Poorly Differentiated Lung Adenocarcinoma Recurring After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified initially; recurrent tumor PD-L1 >50%

The cancer recurred in June 2024 with a para-aortic mass and enlarged mediastinal and supraclavicular lymph nodes. Camrelizumab was started, but he could not tolerate it and declined further treatment.

PubMed CentralRead more →

Poorly Differentiated Lung Adenocarcinoma Without Recurrence After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified; PD-L1 at least 1%

No signs of recurrence were observed through April 2025 after surgery and 4 cycles of adjuvant chemotherapy.

PubMed CentralRead more →

Small-cell lung cancer with anti-GABAb paraneoplastic limbic encephalitis: complete response after radiochemotherapy

Patient Info: Anonymized, Female, 70+

Biomarkers: CSF anti-GABAb antibodies positive

As of May 2025, follow-up imaging after combined radiochemotherapy showed complete resolution of the right hilar lung mass and right medial temporal hypermetabolism, and the patient had no further seizures.

PubMed CentralRead more →

NRG1-Fusion Lung Adenocarcinoma With a Partial Response to Afatinib

Patient Info: Anonymized, female, 50s

Biomarkers: CD74-NRG1 fusion

Afatinib produced a partial response lasting 24 weeks, with progression after 32 weeks on treatment. She died in April 2022.

PubMed CentralRead more →

Metastatic lung squamous cell carcinoma: no recurrence after chemoimmunotherapy and pembrolizumab maintenance

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; PD-L1 TPS 95%; TTF-1-negative; p40-positive

Metastatic Site: mediastinal lymph nodes; bilateral lung nodules

As of April 2025, PET/CT 3 years after treatment initiation showed no sign of recurrence after carboplatin, nab-paclitaxel, pembrolizumab, and 2 years of pembrolizumab monotherapy.

PubMed CentralRead more →

Stage IV squamous lung cancer: partial response complicated by pulmonary artery pseudoaneurysm

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: distant sites not specified (M1c1)

As of April 2025, tumor imaging showed partial remission/significant reduction, and the pulmonary artery pseudoaneurysm was successfully embolized with no recurrent hemoptysis over 6 months.

PubMed CentralRead more →

Metastatic lung adenocarcinoma: pembrolizumab response complicated by pulmonary arterial hypertension

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: CK7-positive; TTF-1-positive; p40 focally positive; high tumor mutational burden; no targetable mutations identified

Metastatic Site: right axillary lymph node; right hilar lymph nodes;…

As of April 2025, the patient was tolerating single-agent pemetrexed without evidence of lung cancer progression, while pulmonary arterial hypertension symptoms had improved on riociguat and macitentan.

PubMed CentralRead more →

Small-Cell Lung Cancer With Later Brain and Other Metastases in a Woman With COPD

Patient Info: Anonymized, female, 50s | Stage IV

Metastatic Site: central nervous system

Her neurologic condition progressively worsened after immune-related encephalitis and extensive metastatic progression. She died from sepsis 8 months after the lung-cancer diagnosis.

PubMed CentralRead more →

Small Cell Lung Cancer That Spread to the Ear Canal

Patient Info: Anonymized, male, 70+ | Stage IV

Metastatic Site: external auditory canal, middle ear, pancreas, bone

The metastatic lesions initially shrank and his hearing and ear pain improved, but he died 15 months after diagnosis.

PubMed CentralRead more →

Stage 4 SMARCA4-deficient lung cancer: ongoing treatment response

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: SMARCA4-deficient lung cancer with BRG-1 loss, CK/CK7 positive, Ki-67 >40%. CEA

Metastatic Site: sigmoid colon, left adrenal gland

After colon metastasis surgery, continued radiotherapy, and later gemcitabine/nedaplatin/bevacizumab/camrelizumab for adrenal metastasis, the cancer showed a favorable response with no further recurrence or new metastasis reported.

PubMed CentralRead more →

Stage II Lung Squamous Cell Carcinoma Complicated by Immunotherapy-Induced Cutaneous Lupus

Patient Info: Anonymized, male, 60s | Stage II

Imaging showed a treatment response. After radical radiotherapy, camrelizumab was discontinued because of immune-mediated subacute cutaneous lupus, and the lung cancer was placed under active monitoring.

PubMed CentralRead more →

Stage 3 squamous cell lung cancer: complete remission on tislelizumab monotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Squamous lung cancer markers: P40 positive, TTF-1/Napsin A negative, Ki-67 75%. PD-1/PD-L1 testing was not done.

As of April 2024, enhanced CT, tumor-marker decline, and clinical assessment supported complete remission by iRECIST after chemoimmunotherapy and tislelizumab monotherapy.

PubMed CentralRead more →

Metastatic lung adenocarcinoma: complete remission on nivolumab complicated by immune-mediated diabetes

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Lung tumor: EGFR wild type, ALK rearrangement not detected. Immune-mediated diabetes: islet/GAD antibodies negative and C-peptide undetectable.

Metastatic Site: brain (cerebellum and occipital lobe); liver

As of March 2025, serial CT and MRI scans through October 2023 showed no evidence of oncologic disease after nivolumab, while immune-mediated diabetes was controlled with basal-bolus insulin.

PubMed CentralRead more →

Stage IV ROS1 Lung Adenocarcinoma: Luna's Patient Story

Patient Info: Luna, Female, 50s | Stage IV

Biomarkers: ROS1 rearrangement; EGFR negative; ALK negative

Metastatic Site: liver; bones

Luna had Stage IV ROS1-positive lung adenocarcinoma with liver and bone metastases. After progression on initial chemotherapy, crizotinib led to tumor shrinkage and controlled her cancer for almost 12 years as of March 2025.

The Patient StoryRead more →

Stage IV KRAS Lung Cancer: Rosemary's Patient Story

Patient Info: Rosemary Conway, female, 60s | Stage IV

Biomarkers: KRAS mutation

After 14 months on daraxonracib in a clinical trial, Rosemary’s Stage IV lung cancer had stopped growing and she had returned to walking and lifting weights.

Dana-FarberRead more →

Extended-stage small cell lung cancer with breast metastasis: complete response after pembrolizumab

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: TMB-high, microsatellite stable; TP53/PTEN mutations, and SOX2/PIK3CA/FGF12 amplifications.

Metastatic Site: breast

As of March 2025, she had maintained complete response for more than 18 months on pembrolizumab monotherapy after prior cisplatin/irinotecan response.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, adrenal gland, liver, thyroid

The cancer progressed after small-cell transformation with adrenal, thyroid, liver and brain involvement, and she died 52.7 months after the original diagnosis from disease progression and organ failure.

PubMed CentralRead more →

Metastatic Lung Cancer With Pulmonary Embolism, Cardiac Tamponade, and Recurrent Stroke

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: leptomeninges

After the lung cancer was diagnosed, she developed leptomeningeal metastases and recurrent ischemic strokes and died the following month.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: liver

The cancer progressed after transformation to small cell lung cancer, and she died 49 months after the original diagnosis.

PubMed CentralRead more →

Etoposide Desensitization After Cardiac Arrest in Metastatic Small Cell Lung Cancer

Patient Info: Anonymized, female, 60s | Stage IV

Metastatic Site: brain

After later tumor progression and further systemic treatment, she died in September 2021 from multifactorial progressive leukoencephalopathy, meningopyoventriculitis, and brain atrophy.

PubMed CentralRead more →

HER2 exon 20 metastatic lung adenocarcinoma with pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 exon 20 insertion lung adenocarcinoma with TP53 mutation, PD-L1 TPS 50%, and low TMB.

Metastatic Site: contralateral lung

Right lower lobectomy with radical lymphadenectomy in November 2023 showed pathologic complete response, and no additional therapy was offered after surgery.

PubMed CentralRead more →

Stage 4 lung adenocarcinoma with RET fusion responding to pralsetinib

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: RET fusion

Metastatic Site: pleura

As of March 2025, he had recovered from grade 3 Pneumocystis jirovecii pneumonia, restarted pralsetinib, and had no progressive disease or recurrence of adverse events over 13 months.

PubMed CentralRead more →

Stage 4 lung cancer: managing pembrolizumab-induced myasthenia gravis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Anti-acetylcholine receptor antibody elevated; TSH elevated during immune-related adverse event workup; cancer biomarkers not reported

At 9 months after the immune-related myasthenia gravis presentation, lung cancer remained in complete response while she continued low-dose prednisolone, pyridostigmine, levothyroxine, and nighttime NIV.

PubMed CentralRead more →

Recurrent lung adenocarcinoma: sick sinus syndrome during anlotinib treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: driver genes negative

Recurrent/progressive lung adenocarcinoma was being treated with anlotinib when sick sinus syndrome developed; the patient received a permanent pacemaker and remained alive under follow-up, but post-pacemaker cancer status was not fully reported.

PubMed CentralRead more →